X0306
4
2020-10-16
0
0001623526
Stoke Therapeutics, Inc.
STOK
0001780082
Liau Gene
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
BEDFORD
MA
01730
0
1
0
0
EVP Research & Preclinical Dev
Common Stock
2020-10-16
4
M
0
5851
0.60
A
19351
D
Common Stock
2020-10-16
4
S
0
5851
40.0003
D
13500
D
Common Stock
2020-10-19
4
M
0
30497
0.60
A
43997
D
Common Stock
2020-10-19
4
M
0
1503
2.19
A
45500
D
Common Stock
2020-10-19
4
S
0
24775
37.6419
D
20725
D
Common Stock
2020-10-19
4
S
0
7225
38.4202
D
13500
D
Employee Stock Option (right to buy)
0.60
2020-10-16
4
M
0
5851
0.00
D
2028-04-02
Common Stock
5851
126566
D
Employee Stock Option (right to buy)
0.60
2020-10-19
4
M
0
30497
0.00
D
2028-04-02
Common Stock
30497
96069
D
Employee Stock Option (right to buy)
2.19
2020-10-19
4
M
0
1503
0.00
D
2028-12-12
Common Stock
1503
70386
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.18 to $38.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.19 to $38.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
The option vested as to 3/48th of the total shares on January 22, 2019, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
/s/ Stephen Tulipano, Attorney-in-Fact
2020-10-20